Child health, 12.5% of the MCQ exam

Chronic paediatric conditions

Asthma, diabetes, epilepsy, cystic fibrosis, ADHD, obesity, food allergy and rheumatic heart disease in children.

High-yield points

  • Childhood asthma: preventer when symptoms are frequent, a written asthma action plan, and a spacer with puffers (not nebulisers) for most.

  • Type 1 diabetes often presents with DKA; new polyuria, polydipsia or weight loss in a child needs same-day glucose testing.

  • Cystic fibrosis is found through newborn screening; confirm with a sweat chloride test.

  • ADHD: diagnosis needs symptoms in more than one setting before age 12; stimulant medicines are S8 and usually initiated by a paediatrician or psychiatrist.

  • Food allergy: an ASCIA action plan and adrenaline autoinjector for those at risk of anaphylaxis.

  • Acute rheumatic fever: Jones criteria (with lower thresholds in high-risk groups); needs long-term benzathine penicillin.

  • Childhood obesity: family-based lifestyle change; screen for complications (sleep apnoea, fatty liver, insulin resistance).

India vs Australia

Where the answer the AMC marks correct differs from what’s usually taught in Indian MBBS.

  • ADHD stimulants

    India (MBBS)

    Psychiatrist prescribed; access varies.

    Australia (AMC): what the exam expects

    Regulated by each state; often specialist initiation, permit or authority needed.

  • Cystic fibrosis

    India (MBBS)

    Under-diagnosed.

    Australia (AMC): what the exam expects

    Picked up on newborn screening; CFTR modulators are PBS-subsidised for eligible patients.

  • Haemoglobinopathies

    India (MBBS)

    Thalassaemia major needing chronic transfusion is common.

    Australia (AMC): what the exam expects

    Uncommon; mainly in families from high-prevalence regions. Offer carrier testing in those groups.

  • Type 1 diabetes

    India (MBBS)

    Insulin and finger-prick testing, often limited by cost.

    Australia (AMC): what the exam expects

    Subsidised CGM and pumps are common; school care plans; NDSS support.

The Australian context

Stimulant prescribing for ADHD is regulated by each state, often requiring specialist initiation or authority. CFTR modulator therapy for cystic fibrosis is PBS-subsidised for eligible patients.